Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease

ACS Chemical Neuroscience

Volumn 4, Issue 11, 2013, Pages 1430-1438

  McFarland, Krista ^a   Spalding, Tracy A ^a,c   Hubbard, David ^a   Ma, Jian Nong ^a   Olsson, Roger ^a,b   Burstein, Ethan S ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

^b LUND UNIVERSITY   (Sweden)

^c Goldfinch Statistical Programming   (United States)

Author keywords

behavior; Bexarotene; dopamine neuron; Nurr1; Parkinson's disease; retinoid X receptor

Indexed keywords

BEXAROTENE; HETERODIMER; HOMODIMER; HORMONE RECEPTOR; NUCLEAR RECEPTOR RELATED FACTOR 1; TRIACYLGLYCEROL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CONTINUOUS INFUSION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; RECEPTOR BINDING; THYROID FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; BEHAVIOR, ANIMAL; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER TECHNIQUES; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; INFUSIONS, SUBCUTANEOUS; INJECTIONS, INTRAVENTRICULAR; MALE; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; PARKINSON DISEASE; PRIMARY CELL CULTURE; PROTEIN MULTIMERIZATION; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDRONAPHTHALENES;

EID: 84888380533     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400100f     Document Type: Article

References (34)

1. Zetterstrom, R. H., Zetterström, R. H., Solomin, L., Jansson, L., Hoffer, B. J., Olson, L., and Perlmann, T. (1997) Dopamine neuron agenesis in Nurr1-deficient mice Science 276, 248-250
2. Kadkhodaei, B., Ito, T., Joodmardi, E., Mattsson, B., Rouillard, C., Carta, M., Muramatsu, S., Sumi-Ichinose, C., Nomura, T., Metzger, D., Chambon, P., Lindqvist, E., Larsson, N. G., Olson, L., Björklund, A., Ichinose, H., and Perlmann, T. (2009) Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons J. Neurosci. 29, 15923-15932
3. Galleguillos, D., Fuentealba, J. A., Gómez, L. M., Saver, M., Gómez, A., Nash, K., Burger, C., Gysling, K., and Andrés, M. E. (2010) Nurr1 regulates RET expression in dopamine neurons of adult rat midbrain J. Neurochem. 114, 1158-1167
4. Hermanson, E., Joseph, B., Castro, D., Lindqvist, E., Aarnisalo, P., Wallén, A., Benoit, G., Hengerer, B., Olson, L., and Perlmann, T. (2003) Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells Exp. Cell Res. 288, 324-334
5. Sacchetti, P., Mitchell, T. R., Granneman, J. G., and Bannon, M. J. (2001) Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism J. Neurochem. 76, 1565-1572
6. Sakurada, K., Sakurada, K., Ohshima-Sakurada, M., Palmer, T. D., and Gage, F. H. (1999) Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain Development 126, 4017-4026
7. Schimmel, J. J., Crews, L., Roffler-Tarlov, S., and Chikaraishi, D. M. (1999) 4.5 kb of the rat tyrosine hydroxylase 5′ flanking sequence directs tissue specific expression during development and contains consensus sites for multiple transcription factors Mol. Brain Res. 74, 1-14
8. Saijo, K., Winner, B., Carson, C. T., Collier, J. G., Boyer, L., Rosenfeld, M. G., Gage, F. H., and Glass, C. K. (2009) A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death Cell 137, 47-59
9. Le, W. D., Xu, P., Jankovic, J., Jiang, H., Appel, S. H., Smith, R. G., and Vassilatis, D. K. (2003) Mutations in NR4A2 associated with familial Parkinson disease Nat. Genet. 33, 85-89
10. Le, W., Pan, T., Huang, M., Xu, P., Xie, W., Zhu, W., Zhang, X., Deng, H., and Jankovic, J. (2008) Decreased NURR1 gene expression in patients with Parkinson's disease J. Neurol. Sci. 273, 29-33
11. Sleiman, P. M., Healy, D. G., Muqit, M. M., Yang, Y. X., Van Der Brug, M., Holton, J. L., Revesz, T., Quinn, N. P., Bhatia, K., Diss, J. K., Lees, A. J., Cookson, M. R., Latchman, D. S., and Wood, N. W. (2009) Characterisation of a novel NR4A2 mutation in Parkinson's disease brain Neurosci. Lett. 457, 75-79
12. Chu, Y., Le, W., Kompoliti, K., Jankovic, J., Mufson, E. J., and Kordower, J. H. (2006) Nurr1 in Parkinson's disease and related disorders J. Comp. Neurol. 494, 495-514
13. Wang, Z., Benoit, G., Liu, J., Prasad, S., Aarnisalo, P., Liu, X., Xu, H., Walker, N. P., and Perlmann, T. (2003) Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors Nature 423, 555-560
14. Dubois, C., Hengerer, B., and Mattes, H. (2006) Identification of a potent agonist of the orphan nuclear receptor Nurr1 ChemMedChem 1, 955-958
15. Hintermann, S., Chiesi, M., von Krosigk, U., Mathé, D., Felber, R., and Hengerer, B. (2007) Identification of a series of highly potent activators of the Nurr1 signaling pathway Bioorg. Med. Chem. Lett. 17, 193-196
16. Ordentlich, P., Yan, Y., Zhou, S., and Heyman, R. A. (2003) Identification of the antineoplastic agent 6-mercaptopurine as an activator of the orphan nuclear hormone receptor Nurr1 J. Biol. Chem. 278, 24791-24799
17. Amoutzias, G. D., Pichler, E. E., Mian, N., De Graaf, D., Imsiridou, A., Robinson-Rechavi, M., Bornberg-Bauer, E., Robertson, D. L., and Oliver, S. G. (2007) A protein interaction atlas for the nuclear receptors: properties and quality of a hub-based dimerisation network BMC Syst. Biol. 1, 34
18. Carpentier, R., Sacchetti, P., Ségard, P., Staels, B., and Lefebvre, P. (2008) The glucocorticoid receptor is a co-regulator of the orphan nuclear receptor Nurr1 J. Neurochem. 104, 777-789
19. Wallen-Mackenzie, A., Mata de Urquiza, A., Petersson, S., Rodriguez, F. J., Friling, S., Wagner, J., Ordentlich, P., Lengqvist, J., Heyman, R. A., Arenas, E., and Perlmann, T. (2003) Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells Genes Dev. 17, 3036-3047
20. Boehm, M. F., Zhang, L., Badea, B. A., White, S. K., Mais, D. E., Berger, E., Suto, C. M., Goldman, M. E., and Heyman, R. A. (1994) Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids J. Med. Chem. 37, 2930-2941
21. Targretin NDA #21055. Information may be found at http://www.accessdata. fda.gov/drugsatfda-docs/nda/99/21055-Targretin.cfm.
22. Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., and Yocum, R. C. (2001) Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results J. Clin. Oncol. 19, 2456-24571
23. Assaf, C., Bagot, M., Dummer, R., Duvic, M., Gniadecki, R., Knobler, R., Ranki, A., Schwandt, P., and Whittaker, S. (2006) Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion Br. J. Dermatol. 155, 261-266
24. Miller, V. A., Benedetti, F. M., Rigas, J. R., Verret, A. L., Pfister, D. G., Straus, D., Kris, M. G., Crisp, M., Heyman, R., Loewen, G. R., Truglia, J. A., and Warrell, R. P., Jr. (1997) Initial clinical trial of a selective retinoid X receptor ligand, LGD1069 J. Clin. Oncol. 15, 790-795
25. Rizvi, N. A., Marshall, J. L., Dahut, W., Ness, E., Truglia, J. A., Loewen, G., Gill, G. M., Ulm, E. H., Geiser, R., Jaunakais, D., and Hawkins, M. J. (1999) A Phase I study of LGD1069 in adults with advanced cancer Clin. Cancer Res. 5, 1658-1664
26. Friling, S., Bergsland, M., and Kjellander, S. (2009) Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease BMC Neurosci. 10, 146-153
27. McFarland, K., Price, D. L., and Bonhaus, D. W. (2011) Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease Behav. Pharmacol. 22, 681-692
28. Rigas, J. R. and Dragnev, K. H. (2005) Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene Oncologist 10, 22-33
29. Lerner, V., Miodownik, C., Gibel, A., Kovalyonok, E., Shleifer, T., Goodman, A. B., and Ritsner, M. S. (2008) Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial Clin. Neuropharmacol. 31, 25-33
30. Dai, Y. B., Tan, X. J., Wu, W. F., Warner, M., and Gustafsson, JÅ. (2012) Liver X receptor β protects dopaminergic neurons in a mouse model of Parkinson disease Proc. Natl. Acad. Sci. U.S.A. 109, 13112-13117
31. Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., Brunden, K. R., Wilson, D. A., and Landreth, G. E. (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models Science 335, 1503-1506
32. Tan, P. K., Wang, J., Littler, P. L., Wong, K. K., Sweetnam, T. A., Keefe, W., Nash, N. R., Reding, E. C., Piu, F., Brann, M. R., and Schiffer, H. H. (2007) Monitoring interactions between receptor tyrosine kinases and their downstream effector proteins in living cells using bioluminescence resonance energy transfer Mol. Pharmacol. 72, 1440-1446
33. Schinelli, S., Zuddas, A., Kopin, I. J., Barker, J. L., and di Porzio, U. (1988) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolism and 1-methyl-4-phenylpyridinium uptake in dissociated cell cultures from the embryonic mesencephalon J. Neurochem. 50, 1900-1907
34. Lerner, V., Miodownik, C., Gibel, A., Sirota, P., Bush, I., Elliot, H., Benatov, R., and Ritsner, M. S. The Retinoid X Receptor Agonist Bexarotene Relieves Positive Symptoms of Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial. J. Clin. Psychiatry, in press.